Pisa syndrome in Parkinson disease: An observational multicenter Italian study. (17th November 2015)

• Record Type: Journal Article
• Authors: Tinazzi, Michele; Fasano, Alfonso; Geroin, Christian; Morgante, Francesca; Ceravolo, Roberto; Rossi, Simone; Thomas, Astrid; Fabbrini, Giovanni; Bentivoglio, Annarita; Tamma, Filippo; Cossu, Giovanni; Modugno, Nicola; Zappia, Mario; Volontè, Maria Antonietta; Dallocchio, Carlo; Abbruzzese, Giovanni; Pacchetti, Claudio; Marconi, Roberto; Defazio, Giovanni; Canesi, Margherita; Cannas, Antonino; Pisani, Antonio; Mirandola, Rina; Barone, Paolo; Vitale, Carmine
• Is Part Of: Neurology. Volume 85:Number 20(2015)
• Publication Date: 2015-11-17
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Neurologie -- Périodiques; 616.8
• DOI: 10.1212/WNL.0000000000002122
• Languages: English
• ISSNs: 0028-3878

Abstract

Abstract : Objective: To estimate the prevalence of Pisa syndrome (PS) in patients with Parkinson disease (PD) and to assess the association between PS and demographic and clinical variables. Methods: In this multicenter cross-sectional study, consecutive outpatients with PD attending 21 movement disorders Italian tertiary centers were enrolled and underwent standardized clinical evaluation. PS was defined as trunk lateral deviation ≥10°. Patients with PD were compared according to the presence of PS for several demographic and clinical variables. Results: Among 1, 631 enrolled patients with PD, PS was detected in 143 patients (8.8%, 95% confidence interval 7.4%–10.3%). Patients with PS were older, had lower body mass index, longer disease duration, higher disease stages, and poorer quality of life. Falls were more frequent in the PS group as well as occurrence of "veering gait" (i.e., the progressive deviation toward one side when patient walked forward and backward with eyes closed). Patients with PS received higher daily levodopa equivalent daily dose and were more likely to be treated with combination of levodopa and dopamine agonists. Osteoporosis and arthrosis were significantly the most frequent associated medical conditions in patients with PS. Multiple explanatory variable logistic regression models confirmed the association of PS with the following variables: Hoehn and Yahr stage, ongoing combined treatment with levodopa and dopamine agonist, associated medical conditions, and presence of veering gait. Conclusions: Our results suggest that PS is a relatively frequent and often disabling complication in PD, especially in the advanced disease stages. The association is dependent on a number of potentially relevant demographic and clinical variables.